AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

12 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

25 Mar 2024 07:00:25 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

19 Mar 2024 20:49:43 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

19 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

14 Mar 2024 16:23:20 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

05 Mar 2024 16:05:49 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

15 Feb 2024 07:00:35 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

30 Jan 2024 07:00:27 By Nasdaq GlobeNewswire

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

05 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

10 Nov 2023 07:00:10 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 15:37:36 By Nasdaq GlobeNewswire

Aquestive Therapeutics Completes $45 Million Debt Refinancing

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Provides Business Update

09 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

20 Sep 2023 08:04:50 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

11 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

23 Aug 2023 07:00:42 By Nasdaq GlobeNewswire